Clinical Trials
First-Line Serplulimab Plus Bevacizumab and Chemotherapy in Recurrent or Metastatic Cervical Cancer
Liu et alFrontiers in immunology

In the multicenter, single-arm, phase II ASTRUM-CC01 trial (NCT05444374), investigators evaluated first-line combination therapy with serplulimab, bevacizumab, cisplatin, and paclitaxel in patients aged 18–75 years with previously untreated recurrent or metastatic (R/M) cervical cancer. Patients received 4 to 6 cycles of the quadruplet combination, followed by maintenance therapy with serplulimab and bevacizumab. The primary endpoint was objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), duration of response, and safety.
Among 48 enrolled patients (43 evaluable for efficacy), the regimen demonstrated substantial antitumor activity, achieving an ORR of 75.00% (95% CI: 60.40–86.36) and a disease control rate (DCR) of 89.58% (95% CI: 77.34–96.53). Median PFS reached 21.23 months (95% CI: 14.43–NR), and the estimated 12-month OS rate was 83.97% (95% CI: 73.66–95.72), although median OS data remain immature. Subgroup analyses revealed that high baseline clinical stage at initial diagnosis was a significant risk factor for worse PFS (HR = 3.01, P = 0.023), whereas PD-L1 expression levels and location of recurrence did not significantly correlate with survival outcomes. The regimen displayed an acceptable safety profile with no new safety signals; grade ≥3 adverse events occurred in 43.75% of patients (n = 21), including fistula events in 10.42% (n = 5).
Key Takeaways
- First-line combination therapy with serplulimab, bevacizumab, and chemotherapy achieved an objective response rate of 75.00% (95% CI: 60.40–86.36) and a disease control rate of 89.58% (95% CI: 77.34–96.53) in patients with recurrent or metastatic cervical cancer.
- Median progression-free survival reached 21.23 months (95% CI: 14.43–NR) with an estimated 12-month overall survival rate of 83.97% (95% CI: 73.66–95.72), though higher initial clinical stage predicted shorter progression-free survival (HR = 3.01, P = 0.023).
- Severe (grade ≥3) adverse events occurred in 43.75% of patients, including fistula events in 10.42%, while PD-L1 expression levels and recurrence site showed no significant correlation with survival outcomes.
Read the original sourceFrontiers in immunology
